• J.P. Morgan has initiated coverage of Septerna (NASDAQ:SEPN) with an overweight rating, citing the company’s platform for GPCR drug design.
• “Notwithstanding manifold newly actionable GPCR targets, we see Septerna (SEPN) executing a highly attractive pipeline strategy, focused on validated targets in large established indications where an oral option offers a clear benefit to patients,” the bank said in a note.
• The bank said it expects Septerna (SEPN) shares to outperform its broader coverage midterm in view of a potential de-risking catalyst for its lead drug candidate in 2025, its cash runway to the second half of 2027, and business development prospects for non-core opportunities.
• J.P. Morgan set its price target for the stock at $38.
• Septerna (SEPN) held its initial public offering in late October.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.